These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1121 related items for PubMed ID: 29566033

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, Zareba W, Goldenberg I.
    Circulation; 2015 Oct 27; 132(17):1613-9. PubMed ID: 26316618
    [Abstract] [Full Text] [Related]

  • 6. Outcome of Patients With In-Hospital Ventricular Tachycardia and Ventricular Fibrillation Arrest While Using a Wearable Cardioverter Defibrillator.
    Ellenbogen KA, Wan C, Shavelle DM.
    Am J Cardiol; 2018 Jan 15; 121(2):205-209. PubMed ID: 29153771
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death.
    Kutyifa V, Vermilye K, Daimee UA, McNitt S, Klein H, Moss AJ.
    Europace; 2018 Sep 01; 20(FI2):f225-f232. PubMed ID: 29905788
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.
    Wu KC, Gerstenblith G, Guallar E, Marine JE, Dalal D, Cheng A, Marbán E, Lima JA, Tomaselli GF, Weiss RG.
    Circ Cardiovasc Imaging; 2012 Mar 01; 5(2):178-86. PubMed ID: 22267750
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, Collier A, Parfrey PS, Connors SP.
    Circ Arrhythm Electrophysiol; 2016 Mar 01; 9(3):. PubMed ID: 26966288
    [Abstract] [Full Text] [Related]

  • 13. Potential roles of the wearable cardioverter-defibrillator in acute phase care of patients at high risk of sudden cardiac death: A single-center Japanese experience.
    Sasaki S, Shoji Y, Ishida Y, Kinjo T, Tsushima Y, Seno M, Nishizaki F, Itoh T, Izumiyama K, Yokota T, Yokoyama H, Yamada M, Horiuchi D, Kimura M, Higuma T, Tomita H, Okumura K.
    J Cardiol; 2017 Jan 01; 69(1):359-363. PubMed ID: 27595899
    [Abstract] [Full Text] [Related]

  • 14. Wearable Cardioverter-Defibrillators following Cardiac Surgery-A Single-Center Experience.
    Heimeshoff J, Merz C, Ricklefs M, Kirchhoff F, Haverich A, Bara C, Kühn C.
    Thorac Cardiovasc Surg; 2019 Mar 01; 67(2):92-97. PubMed ID: 29925094
    [Abstract] [Full Text] [Related]

  • 15. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA, Koneru JN, Sharma PS, Deshpande S, Wan C, Szymkiewicz SJ.
    JACC Clin Electrophysiol; 2017 Mar 01; 3(3):243-250. PubMed ID: 29759518
    [Abstract] [Full Text] [Related]

  • 16. Ventricular Arrhythmia Occurrence and Compliance in Patients Treated With the Wearable Cardioverter Defibrillator Following Percutaneous Coronary Intervention.
    Barraud J, Pinon P, Laine M, Cautela J, Orabona M, Koutbi L, Pinto J, Thuny F, Franceschi F, Paganelli F, Bonello L, Peyrol M.
    Heart Lung Circ; 2018 Aug 01; 27(8):984-988. PubMed ID: 28969980
    [Abstract] [Full Text] [Related]

  • 17. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias.
    Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, Schuller J, Kron J, Nour KA, Cheng A, Ji SY, Feinstein S, Gupta S, Ilg K, Sinno M, Abu-Hashish S, Al-Mallah M, Sauer WH, Ellenbogen K, Morady F, Bogun F.
    Circ Arrhythm Electrophysiol; 2014 Dec 01; 7(6):1109-15. PubMed ID: 25266311
    [Abstract] [Full Text] [Related]

  • 18. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis.
    Opreanu M, Wan C, Singh V, Salehi N, Ahmad J, Szymkiewicz SJ, Thakur RK.
    J Heart Lung Transplant; 2015 Oct 01; 34(10):1305-9. PubMed ID: 26094085
    [Abstract] [Full Text] [Related]

  • 19. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator.
    Mohsen A, Jimenez A, Hood RE, Dickfeld T, Saliaris A, Shorofsky S, Saba MM.
    J Cardiovasc Electrophysiol; 2014 Feb 01; 25(2):171-6. PubMed ID: 24433308
    [Abstract] [Full Text] [Related]

  • 20. The automated implantable cardiac defibrillator. Prophylaxis in cardiac sarcoidosis.
    Paz HL, McCormick DJ, Kutalek SP, Patchefsky A.
    Chest; 1994 Nov 01; 106(5):1603-7. PubMed ID: 7956431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.